This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MYOK MyoKardia (MYOK) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MyoKardia Stock (NASDAQ:MYOK) 30 days 90 days 365 days Advanced Chart Get MyoKardia alerts:Sign Up Key Stats Today's Range$224.91▼$224.9150-Day Range$222.81▼$224.9152-Week Range$42.65▼$225.00VolumeN/AAverage Volume752,969 shsMarket Capitalization$11.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. Read More Receive MYOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MyoKardia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYOK Stock News HeadlinesFulcrum Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FULC | BenzingaMarch 27, 2025 | benzinga.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024November 13, 2024 | markets.businessinsider.comForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology. | Banyan Hill Publishing (Ad)Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide MoatNovember 12, 2024 | morningstar.comMHealthEx Raises $14M led by General Catalyst to Empower Patients and Health Systems to do more with Health DataOctober 21, 2024 | markets.businessinsider.comMavacamten Shows Promise in Heart Failure With Normal to Supranormal EFOctober 1, 2024 | msn.comBristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)September 27, 2024 | seekingalpha.comSepterna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development RolesSeptember 25, 2024 | finance.yahoo.comSee More Headlines MYOK Stock Analysis - Frequently Asked Questions How were MyoKardia's earnings last quarter? MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.16. What other stocks do shareholders of MyoKardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that MyoKardia investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Micron Technology (MU) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2020Today9/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOK CIK1552451 Webwww.myokardia.com Phone650-741-0900FaxN/AEmployees318Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$276.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.99% Return on Assets-42.42% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$33.56 million Price / Sales357.36 Cash FlowN/A Price / Cash FlowN/A Book Value$8.79 per share Price / Book25.59Miscellaneous Outstanding Shares53,323,000Free FloatN/AMarket Cap$11.99 billion OptionableOptionable Beta1.84 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:MYOK) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyoKardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyoKardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYOK Stock Alerts